{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Based on RECIST v1.1","groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"OG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"OG001","title":"Combination"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Some patients unevaluable for PFS","reportingStatus":"POSTED","timeFrame":"3 Months","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"Participants"}